206 related articles for article (PubMed ID: 25583423)
1. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
Yamashita Y
Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
[TBL] [Abstract][Full Text] [Related]
2. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
3. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
5. Endometriosis-associated ovarian carcinomas.
Nissenblatt M
N Engl J Med; 2011 Feb; 364(5):482-3; author reply 484-5. PubMed ID: 21288105
[No Abstract] [Full Text] [Related]
6. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
[TBL] [Abstract][Full Text] [Related]
7. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of ovarian clear cell carcinoma.
Gounaris I; Brenton JD
Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
[TBL] [Abstract][Full Text] [Related]
9. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
[TBL] [Abstract][Full Text] [Related]
10. The origin of ovarian cancer—is it getting clearer?
Birrer MJ
N Engl J Med; 2010 Oct; 363(16):1574-5. PubMed ID: 20942676
[No Abstract] [Full Text] [Related]
11. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
12. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.
Yamashita Y; Akatsuka S; Shinjo K; Yatabe Y; Kobayashi H; Seko H; Kajiyama H; Kikkawa F; Takahashi T; Toyokuni S
PLoS One; 2013; 8(3):e57724. PubMed ID: 23469222
[TBL] [Abstract][Full Text] [Related]
13. A series of ovarian clear cell and endometrioid carcinoma and their association with endometriosis.
Chew S; Tham KF; Ratnam SS
Singapore Med J; 1997 Jul; 38(7):289-91. PubMed ID: 9339094
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the Relationship Between Endometriosis and Epithelial Ovarian Cancer.
del Carmen MG
Obstet Gynecol Surv; 2015 Sep; 70(9):587-95. PubMed ID: 26403563
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
Sato S; Itamochi H; Oumi N; Chiba Y; Oishi T; Shimada M; Sato S; Chikumi J; Nonaka M; Kudoh A; Komatsu H; Harada T; Sugiyama T
Hum Cell; 2016 Oct; 29(4):181-7. PubMed ID: 26960408
[TBL] [Abstract][Full Text] [Related]
16. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
[TBL] [Abstract][Full Text] [Related]
18. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
19. Ovarian clear cell carcinoma occurring in a young patient with endometriosis and long-term ovulation stimulations.
Saylam K; Devreker F; Simon P; Fayt I; Noël JC
Acta Obstet Gynecol Scand; 2006; 85(12):1506-7. PubMed ID: 17260230
[No Abstract] [Full Text] [Related]
20. [Ovarian clear cell borderline tumour: a clinicopathologic analysis].
Gu WY; Zhang LL; Zhang H; Pan QZ; Qu YQ; Tao X; Ning Y
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):622-626. PubMed ID: 30107668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
